Emergent BioSolutions Shuffles CFO, Adds Directors
Ticker: EBS · Form: 8-K · Filed: Jul 12, 2024 · CIK: 1367644
| Field | Detail |
|---|---|
| Company | Emergent Biosolutions Inc. (EBS) |
| Form Type | 8-K |
| Filed Date | Jul 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-change, board-change, management-transition
Related Tickers: EBS
TL;DR
CFO out, new interim CFO in, two new board members elected at Emergent BioSolutions.
AI Summary
Emergent BioSolutions Inc. announced on July 11, 2024, the departure of its Chief Financial Officer, Richard S. Lindahl, effective July 12, 2024. The company also announced the appointment of Douglas L. Schantz as Interim Chief Financial Officer. Additionally, the company elected two new directors, Robert J. Recchia and Dr. David M. Glick, to its Board of Directors, effective July 11, 2024.
Why It Matters
This filing indicates significant leadership changes at Emergent BioSolutions, including the departure of its CFO and the addition of new board members, which could signal strategic shifts or a response to recent performance.
Risk Assessment
Risk Level: medium — Changes in key executive and board positions can introduce uncertainty regarding future strategy and financial management.
Key Players & Entities
- Emergent BioSolutions Inc. (company) — Registrant
- Richard S. Lindahl (person) — Departing Chief Financial Officer
- Douglas L. Schantz (person) — Interim Chief Financial Officer
- Robert J. Recchia (person) — Newly Elected Director
- Dr. David M. Glick (person) — Newly Elected Director
- July 11, 2024 (date) — Date of earliest event reported
- July 12, 2024 (date) — Effective date of CFO departure
FAQ
Who has been appointed as the interim Chief Financial Officer?
Douglas L. Schantz has been appointed as the Interim Chief Financial Officer.
When is Richard S. Lindahl's departure as CFO effective?
Richard S. Lindahl's departure as CFO is effective July 12, 2024.
How many new directors were elected to the Board?
Two new directors, Robert J. Recchia and Dr. David M. Glick, were elected to the Board.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is July 11, 2024.
What is the principal executive office address of Emergent BioSolutions Inc.?
The principal executive office address is 300 Professional Drive, Gaithersburg, Maryland 20879.
Filing Stats: 505 words · 2 min read · ~2 pages · Grade level 12.5 · Accepted 2024-07-12 16:30:14
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share EBS New York Stock
Filing Documents
- ebs-20240711.htm (8-K) — 25KB
- 0001367644-24-000125.txt ( ) — 148KB
- ebs-20240711.xsd (EX-101.SCH) — 2KB
- ebs-20240711_lab.xml (EX-101.LAB) — 22KB
- ebs-20240711_pre.xml (EX-101.PRE) — 13KB
- ebs-20240711_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: July 12, 2024 By: /s/ RICHARD S. LINDAHL Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer